Issue 5 - Feb 3, 2017
CL43-05 (320 downloads)

  • Soon-Shiong drops “MoonShot” trademark, but MD Anderson suit remains unresolved

    Overnight, cancer pharmaceuticals billionaire Patrick Soon-Shiong stopped using the trademark “MoonShot” to describe his health initiatives, opting instead to use the less grabby, but equally ambitious, name “cancer breakthroughs.”

  • Soon-Shiong’s journey from “Rocket Ship” to “MoonShot”—with lots of confusion

    The MD Anderson complaint against Patrick Soon-Shiong and his business entities, filed Nov. 30, 2016, in the U.S. District Court for the Southern District of Texas, argues that the controversial billionaire’s use of the moonshot trademark created confusion that affected both MD Anderson and the White House initiative headed by then Vice President Joe Biden.

  • Cancer groups: Trump travel ban could “retard scientific progress and adversely affect public health”

    President Donald Trump’s recent executive order that temporarily bars travel from seven Muslim-majority countries to the United States will negatively affect research institutions, public health, and innovation, cancer organizations say.

  • Obituary

    LeMaistre, a pioneer of cancer prevention and former MD Anderson president, dies at 92

     

    Charles Aubrey “Mickey” LeMaistre, a former president of MD Anderson Cancer and a pioneer of cancer prevention, died Jan. 27. He was 92.

  • In Brief

    • Keith Flaherty named editor-in-chief of AACR journal Clinical Cancer Research
    • Gottschalk named chair of bone marrow transplantation, cellular therapy at St. Jude
    • Guttridge named associate director for basic research at Ohio State
    • Heath named associate director for translational sciences at Karmanos
    • Howell joins Fox Chase Department of Radiation Oncology
    • NCCN establishes second policy and advocacy fellowship

  • Drugs & Targets

    • MD Anderson, Guardant form partnership to make liquid biopsy standard of care
    • Indivumed to provide tissue samples to Regeneron
    • Addario institute and Scancell form partnership focused on vaccine
    • Perthera enters collaboration with Novartis to identify patients for clinical trials
    • Benitec, Nant Capital initiate head and neck cancer programs
    • GenomeDx joins Astellas in genomic profiling collaboration

  • Funding Opportunities

    SU2C to fund Dream Teams focused on “cancer interception” in pancreas and lungs

    Stand Up To Cancer broke new ground today when the American Association for Cancer Research, its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception” of the pancreas and lungs.

Issue 4 - Jan 27, 2017
CL43-04 (324 downloads)

  • How a “cool” trial in rare cancers was born

    About a year ago, Sandip Patel, a young doctor who had just joined the faculty at University of California San Diego Moores Cancer Center, stopped by to see his mentor, Razelle Kurzrock, chair of the SWOG Early Therapeutics and Rare Cancers Committee.

  • MD Anderson posts $169 million loss for first four months of fiscal 2017

    MD Anderson Cancer Center lost $58 million during the month of December 2016.

    This latest operating loss brings total losses $169.4 million for the first four months of fiscal 2017, which began on Sept. 1, 2016.

  • In Brief

    • Miami Cancer Institute Opens, joins MSKCC Alliance
    • LUNGevity, CancerCare launch helpline
    • White paper shows challenges, progress in immunotherapy
    • Study finds undisclosed conflicts in Twitter posts by oncologists

  • Drugs & Targets

    • FDA approves first drug for marginal zone lymphoma
    • Merck, Domain Therapeutics collaborate in immune-oncology
Issue 3 - Jan 20, 2017
CL43-03 (308 downloads)

  • “Will I still have coverage?” patients ask oncologists as Republicans move to gut Affordable Care Act

    As Congress lays down the groundwork for dismantling the Affordable Care Act, doctors across America are hearing cancer patients speak of their fear of losing access to care if the law known as “Obamacare” is jettisoned without replacement.

  • FDA forms Oncology Center of Excellence, names Richard Pazdur director

    On his last full day as FDA commissioner, Robert Califf announced the formation of the Oncology Center of Excellence and named Richard Pazdur its director.

    The process of forming the center began in June, and Pazdur has been the acting director. Reorganization of the FDA oncology portfolio is an element of the Obama White House Moonshot Initiative.

  • Guest Editorial

    NCI formulary, moonshot and public-private partnerships

    Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.

  • In Brief

    • Richard Goldberg new director of West Virginia University Cancer Institute
    • Justin Klamerus named president of Karmanos Cancer Hospital
    • Werner-Wasik new executive vice chair, radiation oncology integration at Jefferson
    • Northwell Health partners with Indivumed to create cancer research biobank
    • Tempus and University Hospitals/Seidman announce effort to customize treatment
    • Reporting of lung cancer surgery outcomes provides info about quality of care

  • Drugs & Targets

    • Medicinal product designation for TB-403 for medulloblastoma

  • Funding Opportunities

    LUNGevity issues RFA for career development award

    LUNGevity announced a request for applications for translational research for career development awards that will be granted in 2017.

Page 64 of 118« First...1020304050...60616263646566676869...8090100110...Last »